• Earlier this month, Harrow re-launched VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a steroid-sparing prescription therapy for vernal keratoconjunctivitis in children and adults, supported by a broad push on physician education, patient access, and affordability.
• This move targets a historically underserved pediatric eye disease where many patients are inadequately controlled on antihistamines and face risks from long-term steroid use, potentially reshaping VKC treatment patterns.
• We’ll now examine how the VERKAZIA re-launch and its focus on reducing steroid reliance could influence Harrow’s broader investment narrative.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

Harrow Investment Narrative Recap

To own Harrow, you need to believe it can turn a focused ophthalmic portfolio into sustained revenue growth while controlling costs and leverage. The VERKAZIA re-launch modestly supports this thesis by broadening the branded eye-care base beyond VEVYE, IHEEZO, and TRIESENCE, but it does not change that Harrow’s most important near term catalyst is execution on existing guidance and product ramps. The biggest current risk remains concentration in a few key assets and the pressure this puts on hitting ambitious revenue targets.

Among recent announcements, the Phase 3 trial plans for TRIESENCE in post cataract inflammation stand out here. VERKAZIA adds another branded product aimed at steroid sparing care, while TRIESENCE is being tested precisely in a setting where steroids are standard. Taken together, these programs show how Harrow’s pipeline could deepen its role across inflammatory eye conditions and influence whether it can grow into the higher revenue forecasts analysts have outlined.

Yet while VERKAZIA may broaden the story, investors should be aware that concentration in a few products still leaves Harrow exposed if...

Harrow's narrative projects $784.8 million revenue and $246.0 million earnings by 2029.

Uncover how Harrow's forecasts yield a $68.38 fair value, a 63% upside to its current price.

Exploring Other Perspectives

While consensus already assumed revenue could rise about 26 percent a year, the most optimistic analysts were modeling US$865.9 million of sales and US$263.5 million of earnings by 2029, so VERKAZIA’s re-launch might either support those ambitious assumptions or prompt a rethink of how much risk around pricing pressure you are really comfortable with.

Explore 3 other fair value estimates on Harrow - why the stock might be worth just $59.00!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Harrow research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Harrow research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harrow's overall financial health at a glance.

No Opportunity In Harrow?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Find 48 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.